Micronized 2,4,6-triiodophenol for Stable Plasma Concentration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
2,4-disubstituted phenol derivatives used for treating leukotriene-mediated diseases face pharmacokinetic and therapeutic challenges due to difficulty in maintaining a stable concentration range during multiple administration regimes, leading to inadequate therapeutic index and tolerability issues.
Innovation Solution
A micronized composition of 2,4,6-triiodophenol with particle sizes below 20 microns and low water content, optimized for improved pharmacokinetic properties and efficacy, is developed for treating leukotriene-mediated diseases such as pulmonary fibrosis and arthritis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If non-micronized 2,4,6-triiodophenol is administered in multiple doses, then the compound accumulates in the body, but the plasma concentration cannot be maintained within a desired therapeutic range
Solution Approach 1:
The patent applies micronization to change the physical parameter of particle size of 2,4,6-triiodophenol from non-micronized form to micronized form with particle size below 20 microns. This parameter change improves dissolution rate and bioavailability, enabling better control of plasma concentration within the therapeutic range while maintaining appropriate accumulation levels during multiple dose administration
2Reliability
If derivatives of 2,4-disubstituted phenols are used as inhibitors, then therapeutic activity against leukotriene-mediated diseases is achieved, but pharmacokinetic and tolerability drawbacks occur
Solution Approach 1:
The patent changes the physical parameter of the compound from non-micronized to micronized form with particle size below 20 microns. This parameter change improves dissolution rate and bioavailability, leading to more predictable pharmacokinetics and reduced tolerability issues while preserving the therapeutic activity as iNOS inhibitor and L-selectin adhesion molecule inhibitor
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
A composition comprising a 2,4-disubstituted phenol derivative in its micronized form and its use in the treatment of leukotriene-mediated diseases, gastrointestinal-inflammatory diseases or pulmonar fibrosis. More particularly, the present invention refers to use of 2,4,6-triiodophenol for the treatment of pulmonary fibrosis and arthritis.